An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with ...

Learn what to expect after TAVR, including recovery timeline, incision care, managing fatigue, and when to contact your ...

Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad ...

Compare TAVR and redo open heart surgery for aortic valve stenosis, including risks, recovery, valve longevity, and how to ...

Q2 2026 earnings call: sales +12.5%, raised FY guidance, TAVR/TMTT momentum, PROGRESS & NCD catalysts—read key takeaways.

Venus Medtech announced today that it completed enrollment in a pivotal study of its Venus-PowerX TAVR system.

The incidence of cardiovascular disease is rising across the globe, with more than 28 million people worldwide living with ...

Edwards Lifesciences (NYSE:EW) reported second-quarter results that included significant sales growth and increased guidance.

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...

Edwards Lifesciences beat Q2 earnings on the back of a 48% surge in mitral and tricuspid therapies, and raised full-year sales guidance to 10%-11% growth as TAVR durability data and a pending ...

Background Artificial intelligence ECG (AI-ECG) models can predict cardiovascular outcomes, but their clinical adoption is ...